Want to see UFPT full AI Analyst Report?
Top Page
Ufp Technologies
(NASDAQ:UFPT)
Select Model
Select Model
Rating:80Outperform
Price Target:
$318.00
▲(4.53% Upside)
Action:Reiterated
Date:08/07/26
UFPT scores well on fundamentals and momentum: financial performance remains strong with durable margins, attractive returns, and currently conservative leverage, while technicals show a powerful uptrend with positive momentum. The main offsets are a relatively high P/E valuation, signs of near-term cash-flow softness (FCF decline and OCF below net income), and earnings-call risks around inflation, higher SG&A/transition costs, and guidance implying growth normalizes toward the 6–9% range.
Positive Factors
Durable profitability
UFPT’s sustained gross, operating, and net margins show that its engineered, specification-driven manufacturing services generate meaningful value beyond basic production. Stable profitability supports reinvestment in capacity, design capabilities, and regulated medical programs while providing resilience across end markets.
Negative Factors
Growth deceleration
The contrast between strong Q2 growth and slower expected growth suggests that recent acceleration may not represent the company’s sustainable run rate. Moderation toward 6–9% still implies expansion, but it reduces near-term operating leverage and makes future results more dependent on successful program launches.
Read all positive and negative factors
Positive Factors
Negative Factors
Durable profitability
UFPT’s sustained gross, operating, and net margins show that its engineered, specification-driven manufacturing services generate meaningful value beyond basic production. Stable profitability supports reinvestment in capacity, design capabilities, and regulated medical programs while providing resilience across end markets.
Read all positive factors
Ufp Technologies Key Performance Indicators (KPIs)
Any
Net Sales by Market
Revenue distribution across the company’s end markets (for example, food, medical, industrial). Reveals where UFP Technologies gets its sales, how exposed it is to particular industries or economic cycles, and whether growth or weakness is concentrated in a few markets — key for assessing demand risk and upside potential from market diversification.
Revenue distribution across the company’s end markets (for example, food, medical, industrial). Reveals where UFP Technologies gets its sales, how exposed it is to particular industries or economic cycles, and whether growth or weakness is concentrated in a few markets — key for assessing demand risk and upside potential from market diversification.
Data provided by:
The Fly
The FlyUfp Technologies (UFPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.29B
Dividend YieldN/A
Average Volume (3M)110.31K
Price to Earnings (P/E)31.6
Beta (1Y)1.35
Revenue Growth7.32%
EPS Growth7.24%
CountryUS
Employees4,846
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)9.36
Shares Outstanding7,745,790
10 Day Avg. Volume105,456
30 Day Avg. Volume110,308
Financial Highlights & Ratios
PEG Ratio1.63
Price to Book (P/B)4.04
Price to Sales (P/S)2.84
P/FCF Ratio21.66
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.47
Enterprise Value/Gross Profit12.18
Enterprise Value/Ebitda18.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.74
Revenue Forecast (FY)$657.82M
Ufp Technologies Business Overview & Revenue Model
Company Description
UFP Technologies, Inc. specializes in the engineering and custom fabrication of components, subassemblies, finished products, and packaging, primarily utilizing advanced foams, films, and plastics. A significant portion of its business is dedicate...
How the Company Makes Money
UFPT makes money primarily by manufacturing and selling custom-engineered products and components to customers, with its largest revenue stream coming from medical device-related programs. Revenue is generally generated through (1) long-term or pr...
Ufp Technologies Earnings Call Summary
Earnings Call Date:Aug 03, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call highlighted strong, broad-based financial performance—including double-digit revenue and EPS growth, margin expansion, solid cash generation and a healthy M&A pipeline—while also acknowledging near-term headwinds such as raw material inflation, higher SG&A from strategic investments and transition costs, and delayed realization of some cost benefits from transfers to the Dominican Republic. Management expects ongoing growth but cautioned that Q2 comparisons were aided by a weak year-ago quarter and some benefits will realize more slowly than initially planned.Positive Updates
Strong Revenue Growth
Sales increased 15.1% year-over-year to $174.0 million in Q2 FY2026, driven by broad-based contributions across the UFP platform.
Negative Updates
Raw Material Inflation Risk
Inflationary pressure on petroleum-based raw materials due to the conflict in Iran; pricing remains volatile and the company expects to pass increases through to the market.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Sales increased 15.1% year-over-year to $174.0 million in Q2 FY2026, driven by broad-based contributions across the UFP platform.
Read all positive updates
Company Guidance
Management gave no formal full‑year numeric guidance but provided directional metrics: Q2 sales rose 15.1% to $174M with organic growth of 12.4%, gross margin of 29.3% (vs. 28.8% prior year), adjusted operating margin of 17.6%, operating income up 15.5% and adjusted EPS of $2.92 (up 16.8%); they generated ~$15.6M cash from operations, spent $1.2M of CapEx, and ended the quarter with leverage under 1x. They said petroleum‑based raw material inflation will be passed through to customers, Q2 SG&A was $22.8M (including ~ $1.9M wages/benefits and ~ $1.0M noncash equity comp) and that SG&A is roughly the new run‑rate with some transition costs easing mid‑2027, their acquisition pipeline remains robust (5–10 opportunities, roughly $5M–$30M of EBITDA each), two of three DR program transfers are complete (third delayed), robotic surgery programs have launched and are expected to deliver an 8‑figure contribution in 2027, and they reiterated a long‑term organic growth target of 6–9% while expecting to be in that range for the remainder of 2026 (but not at Q2’s double‑digit pace).Ufp Technologies Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 631.64M | 602.80M | 504.42M | 400.07M | 353.79M | 206.32M |
| Gross Profit | 180.00M | 170.41M | 146.69M | 112.22M | 90.26M | 51.11M |
| EBITDA | 116.08M | 111.47M | 95.80M | 68.95M | 67.37M | 29.65M |
| Net Income | 72.30M | 68.31M | 58.98M | 44.92M | 41.79M | 15.89M |
Balance Sheet | ||||||
| Total Assets | 681.91M | 665.74M | 629.00M | 404.14M | 378.19M | 334.13M |
| Cash, Cash Equivalents and Short-Term Investments | 9.04M | 20.30M | 13.45M | 5.26M | 4.45M | 11.12M |
| Total Debt | 136.34M | 154.48M | 206.03M | 46.04M | 68.37M | 84.36M |
| Total Liabilities | 219.48M | 241.86M | 286.24M | 118.05M | 140.65M | 139.69M |
| Stockholders Equity | 462.43M | 423.88M | 342.76M | 286.09M | 237.54M | 194.45M |
Cash Flow | ||||||
| Free Cash Flow | 61.42M | 78.98M | 56.94M | 30.84M | 3.96M | 8.90M |
| Operating Cash Flow | 71.58M | 91.91M | 66.59M | 41.33M | 17.74M | 14.29M |
| Investing Cash Flow | -21.92M | -27.60M | -210.16M | -10.49M | 1.29M | -101.46M |
| Financing Cash Flow | -55.35M | -58.16M | 152.39M | -30.02M | -25.89M | 74.05M |
Ufp Technologies Technical Analysis
Positive
304.21
Price Trends
294.22
Positive
275.66
Positive
248.43
Positive
Market Momentum
0.84
Positive
52.79
Neutral
58.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UFPT, the sentiment is Positive. The current price of 304.21 is above the 20-day moving average (MA) of 295.26, above the 50-day MA of 294.22, and above the 200-day MA of 248.43, indicating a bullish trend. The MACD of 0.84 indicates Positive momentum. The RSI at 52.79 is Neutral, neither overbought nor oversold. The STOCH value of 58.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UFPT.
Ufp Technologies Risk Analysis
Ufp Technologies disclosed 35 risk factors in its most recent earnings report. Ufp Technologies reported the most risks in the "Macro & Political" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ufp Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $2.29B | 31.60 | 16.72% | ― | 7.32% | 7.24% | |
69 Neutral | $4.30B | 34.29 | 7.43% | ― | 2.62% | 53.15% | |
66 Neutral | $1.48B | 26.59 | 5.51% | 0.41% | 3.86% | -48.06% | |
56 Neutral | $782.18M | 35.09 | 4.60% | ― | 5.31% | ― | |
55 Neutral | $29.39M | 28.00 | 2.99% | ― | 6.00% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $926.27M | 70.98 | 1.24% | ― | 0.84% | ― |
* Healthcare Sector Average
UFPT
Ufp Technologies
295.78
95.77
47.88%
CNMD
Conmed
49.25
1.89
3.99%
ITGR
Integer Holdings
126.54
56.34
80.26%
IART
Integra Lifesciences
11.91
-4.02
-25.24%
NSYS
Nortech Systems
10.30
0.36
3.62%
VREX
Varex Imaging
18.42
6.50
54.53%
Ufp Technologies Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
UFP Technologies Updates Investor Presentation and Strategic Outlook
Neutral
Aug 24, 2026
In August 2026, UFP Technologies released updated investor presentation materials outlining its business activities and strategic focus for use in meetings with investors and other audiences. The presentation emphasizes the company’s role in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.